...
首页> 外文期刊>Pediatric transplantation. >Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.
【24h】

Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.

机译:改用依维莫司和小剂量环孢霉素A移植肾病患儿肾小球滤过率丧失的逆转。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Until now there have been no good therapeutic options in children with biopsy-proven transplant nephropathy (TN) and loss of glomerular filtration rate (GFR) while receiving cyclosporine A (CsA), mycophenolate mofetil (MMF) and prednisolone (Pred). In 13 kidney transplanted children (mean age 13 yr, SD 4) with CsA/MMF/Pred immunosuppression, renal biopsy revealed significant TN. MMF was discontinued, CsA dose was reduced to 50% and Everolimus was started (1.6 mg/m(2)/day). Pred was stopped in 10 of 13 patients. The mean GFR was 55 mL/min/1.73 m(2) (SD 24) one yr before switch, 45 mL/min/1.73 m(2) (SD 16, p < 0.05) at the time of switch and 47 mL/min/1.73 m(2) (SD 18, p < 0.05) 12 months later. There were no severe side-effects or acute rejections. Lactate dehydrogenase, cholesterol, creatine kinase, and U-albumin/creatinine ratio did not increase significantly. After six months, the mean certican-C0 level was 4.0 microg/L (SD 1.5) and mean CsA-C0 level was 52 ng/mL (SD 23). The GFR of transplanted kidneys in children with TN improved by changing immunosuppression from CsA/MMF/Pred to everolimus and low-dose CsA.
机译:迄今为止,对于接受活检证实的移植肾病(TN)并接受环孢素A(CsA),霉酚酸酯(MMF)和泼尼松龙(Pred)的肾小球滤过率(GFR)丧失的儿童,尚无良好的治疗选择。在13名接受CsA / MMF / Pred免疫抑制的肾脏移植儿童(平均年龄13岁,SD 4)中,肾脏活检显示出明显的TN。停用MMF,将CsA剂量降低至50%,并开始使用依维莫司(1.6 mg / m(2)/天)。在13位患者中有10位停止了Pred的治疗。切换前一年的平均GFR为55 mL / min / 1.73 m(2)(SD 24),切换时为45 mL / min / 1.73 m(2)(SD 16,p <0.05),切换时为47 mL / min min / 1.73 m(2)(SD 18,p <0.05)12个月后。没有严重的副作用或急性排斥反应。乳酸脱氢酶,胆固醇,肌酸激酶和U-白蛋白/肌酐比例没有明显增加。六个月后,certican-C0的平均水平为4.0 microg / L(SD 1.5),CsA-C0的平均水平为52 ng / mL(SD 23)。通过将免疫抑制从CsA / MMF / Pred改为依维莫司和小剂量CsA,可改善TN儿童肾移植的GFR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号